Ming Chang Chiang

Summary

Publications

  1. Chiang M, Cheng Y, Lin K, Yen C. PPAR? regulates the mitochondrial dysfunction in human neural stem cells with tumor necrosis factor alpha. Neuroscience. 2013;229:118-29 pubmed publisher
    ..The anti-inflammatory effects of PPAR? in the hNSCs with TNF?, and the involved mechanisms were also characterized. ..
  2. Chiang M, Cheng Y, Chen H, Liang Y, Yen C. Rosiglitazone promotes neurite outgrowth and mitochondrial function in N2A cells via PPARgamma pathway. Mitochondrion. 2014;14:7-17 pubmed publisher
    ..Furthermore, Rosi increases the level of ATP, D-loop, and mitochondrial mass in N2A cells. Collectively, these findings provide an array of evidence that PPAR? activation provides beneficial neuronal networks within neurite outgrowth. ..
  3. Chung M, Chen Y, Pei D, Cheng Y, Sun B, Nicol C, et al. The neuroprotective role of metformin in advanced glycation end product treated human neural stem cells is AMPK-dependent. Biochim Biophys Acta. 2015;1852:720-31 pubmed publisher
    ..This study further suggests that AMPK may be a potential therapeutic target for treating diabetic neurodegeneration. ..
  4. Chiang M, Cheng Y, Nicol C, Lin K, Yen C, Chen S, et al. Rosiglitazone activation of PPARγ-dependent signaling is neuroprotective in mutant huntingtin expressing cells. Exp Cell Res. 2015;338:183-93 pubmed publisher
    ..Further, our data also support the concept that PPARγ may be a novel therapeutic target for treating HD. ..
  5. Lin C, Nicol C, Cheng Y, Chen S, Yen C, Huang R, et al. Rosiglitazone rescues human neural stem cells from Amyloid-beta induced ER stress via PPAR? dependent signaling. Exp Cell Res. 2018;: pubmed publisher
    ..These findings also improve our understanding of the role of PPAR? in hNSCs, and may aid in the development and implementation of new therapeutic strategies for the treatment of AD. ..
  6. Chiang M, Nicol C, Cheng Y, Lin K, Yen C, Lin C. Rosiglitazone activation of PPARγ-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction and oxidative stress. Neurobiol Aging. 2016;40:181-190 pubmed publisher
  7. Chiang M, Chern Y, Juo C. The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease. Biochim Biophys Acta. 2011;1812:1111-20 pubmed publisher
    ..These findings show that the impairment of PPAR? contributes to the liver dysfunction observed in HD. Treatment with PPAR? agents (TZD and rosiglitazone) enhanced the function of PPAR?, and might lead to therapeutic benefits. ..
  8. Chiang M, Cheng Y, Chen S, Yen C, Huang R. Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against Amyloid-beta-induced mitochondrial dysfunction. Exp Cell Res. 2016;347:322-31 pubmed publisher
    ..Thus, a better understanding of AMPK might assist in both the recognition of its critical effects and the implementation of new therapeutic strategies in the treatment of AD. ..
  9. Chung M, Nicol C, Cheng Y, Lin K, Chen Y, Pei D, et al. Metformin activation of AMPK suppresses AGE-induced inflammatory response in hNSCs. Exp Cell Res. 2017;352:75-83 pubmed publisher
    ..These findings extend our understanding of the central role of AMPK in AGE induced inflammatory responses, which increase the risk of neurodegeneration in diabetic patients. ..

More Information

Publications12

  1. Lin C, Cheng Y, Nicol C, Lin K, Yen C, Chiang M. Activation of AMPK is neuroprotective in the oxidative stress by advanced glycosylation end products in human neural stem cells. Exp Cell Res. 2017;359:367-373 pubmed publisher
  2. Chiang M, Cheng Y, Nicol C, Lin C. The neuroprotective role of rosiglitazone in advanced glycation end product treated human neural stem cells is PPARgamma-dependent. Int J Biochem Cell Biol. 2017;92:121-133 pubmed publisher
  3. Chiang M, Nicol C, Cheng Y. Resveratrol activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced inflammation and oxidative stress. Neurochem Int. 2018;115:1-10 pubmed publisher